Difference between revisions of "Fibrinogen A alpha-chain associated amyloidosis"

Jump to: navigation, search
(Screening)
(CT scan)
Line 13: Line 13:
  
 
==Classification==
 
==Classification==
 
+
<br />
 
==Pathophysiology==
 
==Pathophysiology==
 
Fibrinogen is a plasma protein with a crucial role in the coagulation cascade through its conversion to fibrin
 
Fibrinogen is a plasma protein with a crucial role in the coagulation cascade through its conversion to fibrin
Line 28: Line 28:
  
 
==Causes==
 
==Causes==
 
+
<br />
 
==Epidemiology and Demographics==
 
==Epidemiology and Demographics==
 
is emerging as the most common type of all hereditary renal amyloid diseases in the United Kingdom and Europe.   
 
is emerging as the most common type of all hereditary renal amyloid diseases in the United Kingdom and Europe.   
Line 55: Line 55:
  
 
===X-ray===
 
===X-ray===
 +
There are no x-ray findings associated with fibrinogden amyloidosis.
  
 
===Echocardiography or Ultrasound===
 
===Echocardiography or Ultrasound===

Revision as of 23:59, 5 November 2019

WikiDoc Resources for Fibrinogen A alpha-chain associated amyloidosis

Articles

Most recent articles on Fibrinogen A alpha-chain associated amyloidosis

Most cited articles on Fibrinogen A alpha-chain associated amyloidosis

Review articles on Fibrinogen A alpha-chain associated amyloidosis

Articles on Fibrinogen A alpha-chain associated amyloidosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Fibrinogen A alpha-chain associated amyloidosis

Images of Fibrinogen A alpha-chain associated amyloidosis

Photos of Fibrinogen A alpha-chain associated amyloidosis

Podcasts & MP3s on Fibrinogen A alpha-chain associated amyloidosis

Videos on Fibrinogen A alpha-chain associated amyloidosis

Evidence Based Medicine

Cochrane Collaboration on Fibrinogen A alpha-chain associated amyloidosis

Bandolier on Fibrinogen A alpha-chain associated amyloidosis

TRIP on Fibrinogen A alpha-chain associated amyloidosis

Clinical Trials

Ongoing Trials on Fibrinogen A alpha-chain associated amyloidosis at Clinical Trials.gov

Trial results on Fibrinogen A alpha-chain associated amyloidosis

Clinical Trials on Fibrinogen A alpha-chain associated amyloidosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Fibrinogen A alpha-chain associated amyloidosis

NICE Guidance on Fibrinogen A alpha-chain associated amyloidosis

NHS PRODIGY Guidance

FDA on Fibrinogen A alpha-chain associated amyloidosis

CDC on Fibrinogen A alpha-chain associated amyloidosis

Books

Books on Fibrinogen A alpha-chain associated amyloidosis

News

Fibrinogen A alpha-chain associated amyloidosis in the news

Be alerted to news on Fibrinogen A alpha-chain associated amyloidosis

News trends on Fibrinogen A alpha-chain associated amyloidosis

Commentary

Blogs on Fibrinogen A alpha-chain associated amyloidosis

Definitions

Definitions of Fibrinogen A alpha-chain associated amyloidosis

Patient Resources / Community

Patient resources on Fibrinogen A alpha-chain associated amyloidosis

Discussion groups on Fibrinogen A alpha-chain associated amyloidosis

Patient Handouts on Fibrinogen A alpha-chain associated amyloidosis

Directions to Hospitals Treating Fibrinogen A alpha-chain associated amyloidosis

Risk calculators and risk factors for Fibrinogen A alpha-chain associated amyloidosis

Healthcare Provider Resources

Symptoms of Fibrinogen A alpha-chain associated amyloidosis

Causes & Risk Factors for Fibrinogen A alpha-chain associated amyloidosis

Diagnostic studies for Fibrinogen A alpha-chain associated amyloidosis

Treatment of Fibrinogen A alpha-chain associated amyloidosis

Continuing Medical Education (CME)

CME Programs on Fibrinogen A alpha-chain associated amyloidosis

International

Fibrinogen A alpha-chain associated amyloidosis en Espanol

Fibrinogen A alpha-chain associated amyloidosis en Francais

Business

Fibrinogen A alpha-chain associated amyloidosis in the Marketplace

Patents on Fibrinogen A alpha-chain associated amyloidosis

Experimental / Informatics

List of terms related to Fibrinogen A alpha-chain associated amyloidosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Synonyms and Keywords: Fibrinogen amyloidosis

Overview

Fibrinogen A a-chain (AFib) amyloidosis is a systemic disease caused by extracellular deposition of insoluble amyloid fibrils composed of abnormal fibrinogen, arising from autosomal-dominant mutations in the gene encoding AFib.

Historical Perspective

Fibrinogen amyloidosis was first discovered by Dr Merill Benson et al, an American physician, in 1993.[1]

Classification


Pathophysiology

Fibrinogen is a plasma protein with a crucial role in the coagulation cascade through its conversion to fibrin

It is composed of 2 identical sets of 3 polypeptide chains termed A α, B β, and γ, joined by disulfide bridging.

Each polypeptide is encoded by a distinct gene, FGA, FGB, and FGG.

The gene for the fibrinogen A α-chain with 610 amino acid residues is localized on chromosome 4 and has 6 exons.[2]

Mutations in any of the 3 genes encoding for fibrinogen polypeptides can cause dysfibrinogenemias, coagulation disorders caused by a variety of structural abnormalities in the fibrinogen molecule that result in abnormal fibrinogen function.

Recently identified mutations in the A α-chain gene can lead to hereditary systemic amyloidosis.[3]

Causes


Epidemiology and Demographics

is emerging as the most common type of all hereditary renal amyloid diseases in the United Kingdom and Europe.

A tertiary US amyloid reference center suggestsfibrinogen A alpha-chain amyloidosis is the leading cause of hereditary renal amyloidosis associated with nephrotic syndrome in the United States.

Risk Factors

Screening

There is insufficient evidence to recommend routine screening for Fibrinogen A a-chain amyloidosis.

Natural History, Complications, and Prognosis

Patients with fibrinogen amyloidosis usually develop chronic kidney disease, typically progressing to end-stage renal disease within 5 years of recognition of renal involvement.[4]

Diagnosis

Diagnostic Study of Choice

There is no single diagnostic study of choice for the diagnosis of fibrinogden amyloidosis, but it can be diagnosed based on the occurrence of proteinuric nephropathy, positive family history, identification of amyloid deposits in affected tissues by immunohistochemistry or mass spectrometry, and detection of an FGA amyloidogenic genetic variant.[5]

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

There are no x-ray findings associated with fibrinogden amyloidosis.

Echocardiography or Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Fibrinogen production is exclusively hepatic. Isolated renal transplantation as a treatment for renal failure in fibrinogen amyloidosis is of limited value.[6]

Surgery

Primary Prevention

Secondary Prevention

References

  1. Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R (1993). "Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain". Nat Genet. 3 (3): 252–5. doi:10.1038/ng0393-252. PMID 8097946.
  2. Matsuda M, Sugo T (2001). "Hereditary disorders of fibrinogen". Ann N Y Acad Sci. 936: 65–88. doi:10.1111/j.1749-6632.2001.tb03494.x. PMID 11460526.
  3. Benson MD (2005). "Ostertag revisited: the inherited systemic amyloidoses without neuropathy". Amyloid. 12 (2): 75–87. doi:10.1080/13506120500106925. PMID 16011983.
  4. Tavares I, Oliveira JP, Pinho A, Moreira L, Rocha L, Santos J; et al. (2017). "Unrecognized Fibrinogen A α-Chain Amyloidosis: Results From Targeted Genetic Testing". Am J Kidney Dis. 70 (2): 235–243. doi:10.1053/j.ajkd.2017.01.048. PMID 28359658.
  5. Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH; et al. (2009). "Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis". J Am Soc Nephrol. 20 (2): 444–51. doi:10.1681/ASN.2008060614. PMC 2637055. PMID 19073821.
  6. Mousson C, Heyd B, Justrabo E, Rebibou JM, Tanter Y, Miguet JP; et al. (2006). "Successful hepatorenal transplantation in hereditary amyloidosis caused by a frame-shift mutation in fibrinogen Aalpha-chain gene". Am J Transplant. 6 (3): 632–5. doi:10.1111/j.1600-6143.2005.01199.x. PMID 16468976.



Linked-in.jpg